With nearly 60,000 employees working in this industry cluster, including healthcare workers, it is one of the strongest in the region. With world class institutional and academic assets to leverage, this region has become a focus of biomedical expertise and development.
We have several early-stage and mature bioscience companies working on treatments for co-morbidities such as diabetes, migraines, rare diseases, cancer, and more. In 2020, NIH provided over $567 million in grants to colleges, universities, and private ventures in Greater New Haven.
In 2020, the following Greater New Haven companies received funding from the National Institute of Public Health:
-
ALLYX THERAPEUTICS INC.
-
CAROGEN CORPORATION
-
CENTER FOR PROGRESSIVE RECOVERY, LLC
-
CONNECTICUT AGRICULTURAL EXPERIMENT STATION
-
CORNOVUS PHARMACEUTICALS, INC.
-
CYBREXA, INC.
-
HASKINS LABORATORIES, INC.
-
JOHN B. PIERCE LABORATORY, INC.
-
L2 DIAGNOSTICS, LLC
-
OUI THERAPEUTICS, LLC
-
PROTEOWISE, INC.
-
RENETX BIO, INC.
-
SOUTHERN CONNECTICUT STATE UNIVERSITY
-
THETIS PHARMACEUTICALS, LLC
-
VIRSCIO, INC.
-
YALE UNIVERSITY